Hangzhou Jianjia Medical Technology Co., Ltd has received marketing approval from China’s National Medical Products Administration (NMPA) for its Arthrobot surgical robot, a significant step for the company as it looks to enhance precision in orthopedic procedures. The Arthbot is a multifunctional device capable of performing joint replacement surgeries, including those of the hip, knee, and unicompartmental areas. This approval underscores the rapid advancement of medical technology in China and the growing trend towards robotic-assisted surgery, which promises to improve patient outcomes through increased accuracy and reduced invasiveness.- Flcube.com
Recent news:
-
Sino Biopharmaceutical Submits NDA for Anlotinib and Penpulimab Combo in HCC to NMPA -
Sihuan Pharmaceutical's Huisheng Pharm Strikes Exclusive Deal for Semaglutide Biosimilar in China -
Innovent Biologics' IBI354 Earns Breakthrough Therapy Designation for Ovarian Cancer Treatment -
CDE Includes Double-Crane's Hydroxocobalamine and Sanofi Genzyme's Fitusiran in Rare Disease Care Plan -
Apeiron Therapeutics Initiates Phase Ia/B Study for GTA182 in Solid Tumors with MTAP Deficiency
